Lixte Biotechnology Holdings Inc (LIXT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lixte Biotechnology Holdings Inc (LIXT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10039
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lixte Biotechnology Holdings Inc (Lixte) is a clinical stage pharmaceutical company, which focuses on the discovery of novel drugs for the treatment of cancer and non-malignant diseases. It develops comprises two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company’s product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as solid tumors, acute ischemia and Gaucher’s disease, among others. Its lead compound, LB-100 is being developed in Phase I clinical trials. Lixte established a cooperative research and development agreement with National Institute of Neurological Disorders and Stroke of the National Institutes of Health for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.

Lixte Biotechnology Holdings Inc (LIXT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 10
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 11
Equity Offering 12
Lixte Biotech Raises USD1.5 Million in Public Offering of Shares 12
Lixte Biotech Raises USD1 Million in Private Placement of Shares 13
Lixte Biotechnology Raises USD1.8 Million in Private Placement of Preferred Stock 14
Lixte Biotech Raises USD1.8 Million in Private Placement of Series A Convertible Preferred Stock 15
Lixte Biotech Raises USD1.8 Million in Private Placement of Shares 16
Lixte Biotechnology Holdings Inc – Key Competitors 17
Lixte Biotechnology Holdings Inc – Key Employees 18
Lixte Biotechnology Holdings Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Aug 08, 2018: Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD join Lixte Biotechnology’s board of directors 20
Clinical Trials 21
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lixte Biotechnology Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 10
Lixte Biotech Enters into R&D Agreement with National Institute of Neurological Disorders and Stroke 11
Lixte Biotech Raises USD1.5 Million in Public Offering of Shares 12
Lixte Biotech Raises USD1 Million in Private Placement of Shares 13
Lixte Biotechnology Raises USD1.8 Million in Private Placement of Preferred Stock 14
Lixte Biotech Raises USD1.8 Million in Private Placement of Series A Convertible Preferred Stock 15
Lixte Biotech Raises USD1.8 Million in Private Placement of Shares 16
Lixte Biotechnology Holdings Inc, Key Competitors 17
Lixte Biotechnology Holdings Inc, Key Employees 18

List of Figures
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lixte Biotechnology Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Lixte Biotechnology Holdings Inc (LIXT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Senetas Corporation Limited:企業の戦略・SWOT・財務情報
    Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Senetas Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Celanese Corp (CE):企業の財務・戦略的SWOT分析
    Celanese Corp (CE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • NTUC Income Insurance Co-operative Limited:企業の戦略的SWOT分析
    NTUC Income Insurance Co-operative Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Sojitz Corp (2768):企業の財務・戦略的SWOT分析
    Sojitz Corp (2768) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bio Techne Corp (TECH)-製薬・医療分野:企業M&A・提携分析
    Summary Bio Techne Corp (Bio Techne), develops manufactures and sells biotechnology products and instruments for research and clinical diagnostics. The company provides proteins and antibodies, and related immunoassays and other reagents for research under brands such as R&D Systems, Novus, Biologic …
  • Advance Pharmaceutical Co Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Advance Pharmaceutical Co Ltd (APC), formerly Dang Ling is a healthcare products provider that manufactures and distributes prescription and over the counter pharmaceutical products. The company’s products include vitamins and supplements, cough syrups, skin care, disinfectant liquids, and r …
  • Pathogenetix Inc-医療機器分野:企業M&A・提携分析
    Summary Pathogenetix Inc (Pathogenetix), formerly US Genomics, a subsidiary of Toxic Reports LLC is a medical device company that develops an automated system for bacterial strain typing from complex samples. The company develops products and applications based on its proprietary genome sequence sca …
  • Bentley Systems Incorporated:企業のM&A・事業提携・投資動向
    Bentley Systems Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bentley Systems Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • McBride plc (MCB):企業の財務・戦略的SWOT分析
    McBride plc (MCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Goodman Manufacturing Company LP:企業の戦略・SWOT・財務情報
    Goodman Manufacturing Company LP - Strategy, SWOT and Corporate Finance Report Summary Goodman Manufacturing Company LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Intas Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Intas Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Pfizer Ltd India (PFIZER):企業の財務・戦略的SWOT分析
    Summary Pfizer Ltd India (Pfizer India), a subsidiary of Pfizer Inc, is a pharmaceutical company that develops medicines for brain disorders. The company’s products portfolio comprises of anti-allergics, anti-diabetics, anti-histamines, anti-infectives, anti-parasitics, drugs for cardiovascular and …
  • OKD as:企業の戦略・SWOT・財務情報
    OKD as - Strategy, SWOT and Corporate Finance Report Summary OKD as - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Electricity Generating Public Co Ltd:発電所・企業SWOT分析
    Electricity Generating Public Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Motorola Solutions, Inc.:企業の戦略・SWOT・財務情報
    Motorola Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Motorola Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Magnotta Winery Corporation:企業の戦略・SWOT・財務情報
    Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report Summary Magnotta Winery Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析
    Summary BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza s …
  • IDBI Bank Ltd:企業の戦略・SWOT・財務情報
    IDBI Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary IDBI Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Amerinac Holding Corp.:企業の戦略・SWOT・財務情報
    Amerinac Holding Corp. - Strategy, SWOT and Corporate Finance Report Summary Amerinac Holding Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Wabash Valley Power Association, Inc.:企業の戦略的SWOT分析
    Wabash Valley Power Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆